Quest Diagnostics 2000 Annual Report Download - page 46

Download and view the complete annual report

Please find page 46 of the 2000 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 108

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108

26
12215) and incorporated herein by reference)
4.2 Form of Amendment No. 1 effective as of July 1, 1999 to the Rights Agreement (filed as
an exhibit to the Company’s current report on Form 8-K (Date of Report: August 16,
1999)and incorporated herein by reference)
4.3 Form of Amendment No. 2 to the Rights Agreement (filed as an Exhibit to the Company’s
1999 annual report on Form 10-K and incorporated herein by reference)
4.4 Form of Amendment No. 3 to the Rights Agreement
10.1 Form of Tax Sharing Agreement among Corning Incorporated, Corning Clinical
Laboratories Inc. and Covance Inc. (filed as an Exhibit to the Company’s Registration
Statement on Form 10 (File No. 1-12215) and incorporated herein by reference)
10.2 Form of Spin-Off Distribution Tax Indemnification Agreement between Corning
Incorporated and Corning Clinical Laboratories Inc. (filed as an Exhibit to the Company’s
Registration Statement on Form 10 (File No. 1-12215) and incorporated herein by
reference)
10.3 Form of Spin-Off Distribution Tax Indemnification Agreement between Corning Clinical
Laboratories Inc. and Covance Inc. (filed as an Exhibit to the Company’s Registration
Statement on Form 10 (File No. 1-12215) and incorporated herein by reference)
10.4 Form of Spin-Off Distribution Tax Indemnification Agreement between Covance Inc. and
Corning Clinical Laboratories Inc. (filed as an Exhibit to the Company’s Registration
Statement on Form 10 (File No. 1-12215) and incorporated herein by reference)
10.5 Form of Executive Retirement Supplemental Plan (filed as an Exhibit to the Company’s
Registration Statement on Form 10 (File No. 1-12215) and incorporated herein by
reference)
10.6 Form of Variable Compensation Plan (filed as an Exhibit to the Company’s Registration
Statement on Form 10 (File No. 1-12215) and incorporated herein by reference)
10.7 Stock and Asset Purchase Agreement dated as of February 9, 1999 among SmithKline
Beecham plc, SmithKline Beecham Corporation and the Company (the “Stock and Asset
Purchase Agreement”) (filed as Appendix A of the Company’s Definitive Proxy
Statement dated May 11, 1999 and incorporated by reference)
10.8 Amendment No. 1 dated August 6, 1999 to the Stock and Asset Purchase Agreement
(filed as an exhibit to the Company’s current report on Form 8-K (Date of Report: August
16, 1999) and incorporated herein by reference)
10.9 Non-Competition Agreement dated as of August 16, 1999 between SmithKline Beecham
plc and the Company (filed as an exhibit to the Company’s current report on Form 8-K
(Date of Report: August 16, 1999) and incorporated herein by reference)
10.10 Stockholders Agreement dated as of August 16, 1999 between SmithKline Beecham plc
and the Company (filed as an exhibit to the Company’s current report on Form 8-K (Date
of Report: August 16, 1999) and incorporated herein by reference)
10.11 Category One Data Access Agreement dated as of August 16, 1999 between SmithKline
Beecham plc and the Company (filed as an exhibit to the Company’s current report on
Form 8-K (Date of Report: August 16, 1999) and incorporated herein by reference)
10.12 Global Clinical Trials Agreement dated as of August 16, 1999 between SmithKline
Beecham plc and the Company (filed as an exhibit to the Company’s current report on
Form 8-K (Date of Report: August 16, 1999) and incorporated herein by reference)
10.13 Credit Agreement dated as of August 16, 1999 among the Company, as Borrower, the
Guarantors party thereto, Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith
Incorporated, as Joint Lead Arranger and Syndication Agent, Banc of America Securities
LLC, as Joint Lead Arranger, Bank of America, N.A., as Administrative Agent, Wachovia
Bank N.A., as Co-Documentation Agent, The Bank of New York, as Co-Documentation
Agent and the Lenders party thereto (filed as an exhibit to the Company’s current report
on Form 8-K (Date of Report: August 16, 1999) and incorporated herein by reference)
10.14 Amendment No. 1 to the Credit Agreement (filed as an exhibit to the Company’s 1999
annual report on Form 10-K and incorporated herein by reference)
10.15 Amendment No. 2 to the Credit Agreement (filed as an exhibit to the Company’s quarterly
report on Form 10-Q for the quarter ended September 30, 2000 and incorporated herein by
reference)
10.16 Security Agreement dated as of August 16, 1999 among the Company, each of the
Guarantors party thereto and Bank of America, N.A., as Administrative Agent (filed as an
exhibit to the Company’s current report on Form 8-K (Date of Report: August 16, 1999)
and incorporated herein by reference)